Compare Neurocrine Biosciences Inc (NBIX) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Walmart Stores Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Walmart Stores Inc trades at $106.12 (market cap $841.37B). The key difference: Walmart Stores Inc is far larger — about 53.4× Neurocrine Biosciences Inc's market cap, and Walmart Stores Inc pays a 0.93% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WMT | |
|---|---|---|
Market Cap | $15.77B | $841.37B |
Sector | Health | Consumer Staples |
52-Week High | $185.50 | $134.20 |
52-Week Low | $123.10 | $100.41 |
Enterprise Value | $15.78B | $903.60B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Walmart (WMT) trades at $105.83, down 1.22% on the day, amid a bearish technical signal but strong fundamental performance. The company has beaten EPS estimates for three consecutive quarters, with revenue reaching $680.99 billion in 2025 and net income margin improving to 2.85%. Analyst consensus is strongly bullish with a $130.69 price target, though technical indicators show near-term resistance around $107.
The outlook remains positive given consistent earnings beats, expanding profit margins, and strategic initiatives in delivery and AI. Key risks include competitive pressure from Amazon, which recently surpassed Walmart in revenue, and potential margin compression from increased investment. The stock offers a compelling long-term growth story supported by operational efficiency and market dominance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
